Short selling ban raises hopes for biotech stocks rise - KBR
| 068760 Stock | KRW 62,400 900.00 1.46% |
About 51% of Celltrion Pharm's investors are presently thinking to get in. The analysis of current outlook of investing in Celltrion Pharm suggests that some traders are interested regarding Celltrion Pharm's prospects. The current market sentiment, together with Celltrion Pharm's historical and current headlines, can help investors time the market. In addition, many technical investors use Celltrion Pharm stock news signals to limit their universe of possible portfolio assets.
Celltrion |
Short selling ban raises hopes for biotech stocks rise KBR
Read at news.google.com
 |
Celltrion Pharm Fundamental Analysis
We analyze Celltrion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celltrion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celltrion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Celltrion Pharm is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Celltrion Pharm Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Celltrion Pharm stock to make a market-neutral strategy. Peer analysis of Celltrion Pharm could also be used in its relative valuation, which is a method of valuing Celltrion Pharm by comparing valuation metrics with similar companies.
Peers
Celltrion Pharm Related Equities
| 086900 | Medy Tox | 0.40 |
| ||
| 036830 | Soulbrain Holdings | 6.10 |
|
Complementary Tools for Celltrion Stock analysis
When running Celltrion Pharm's price analysis, check to measure Celltrion Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celltrion Pharm is operating at the current time. Most of Celltrion Pharm's value examination focuses on studying past and present price action to predict the probability of Celltrion Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celltrion Pharm's price. Additionally, you may evaluate how the addition of Celltrion Pharm to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |